Xdynia LLC President to Address Mid-Atlantic Bio Conference

Dr. Yuri Maricich Featured as Emerging Growth Presenter

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Xdynia LLC, a preclinical pharmaceutical company developing drugs for the treatment of neuropathic pain, announced today that President Yuri Maricich, MD, MBA, is to speak at the 2012 Mid-Atlantic Bio Conference in Bethesda, Maryland, September 27-28, 2012. Dr. Maricich will present Xdynia’s innovative business and therapeutic strategies to an audience of more than 850 people, including investors, scientists and advisors from the life sciences sector.

“I am grateful and excited for the opportunity to raise awareness of our efforts to develop T-type calcium channel inhibitors for the treatment of chronic pain, chemotherapy-induced neuropathy, and tremor. We believe that we have the potential to transform treatment with orally bioavailable and non-addictive medications”

“I am grateful and excited for the opportunity to raise awareness of our efforts to develop T-type calcium channel inhibitors for the treatment of chronic pain, chemotherapy-induced neuropathy, and tremor. We believe that we have the potential to transform treatment with orally bioavailable and non-addictive medications,” said Maricich.

Chronic pain affects over 76 million Americans with 60% reporting no relief of symptoms. Maricich notes that the Cav3.2 T-type calcium channel is a common pathway in the development of neuropathic pain from diabetes, shingles, fibromyalgia, cancer, HIV, trauma, phantom limb and chemotherapy. Because chronic pain is responsible for 20% of all outpatient visits and 12% of all prescriptions, with relatively few patients experiencing complete relief, drugs that are orally bioavailable and non-addictive with limited side-effects would provide for an enormous, unmet medical need.

Xdynia is a spin-out company of Tau Therapeutics LLC, a world leader in developing T-type calcium channel products for the treatment of cancer.

About Xdynia

Xdynia LLC is a Charlottesville, Virginia based preclinical pharmaceutical company developing drugs that inhibit Cav3.2 for the treatment of neuropathic pain, chemotherapy-induced neuropathy, and tremor. Xdynia's library of Cav3.2 inhibitors were developed by world experts in T-type calcium channels.

Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Xdynia LLC disclaims any intent or obligation to update forward-looking statements, except as required by law.